Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
59 hedge funds and large institutions have $24.3M invested in Zynerba Pharmaceuticals, Inc in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 8 increasing their positions, 20 reducing their positions, and 20 closing their positions.
3% less funds holding
Funds holding: 61 → 59 (-2)
6% less capital invested
Capital invested by funds: $25.8M → $24.3M (-$1.51M)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
60% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 20
72% less call options, than puts
Call options by funds: $1.26M | Put options by funds: $4.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.24M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.23M |
| 3 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$836K |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$782K |
| 5 |
ECM
Element Capital Management
New York
|
+$525K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.89M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.7M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$1.07M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$717K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$478K |
ZYNE Hedge Fund Activity: Q2 2018 in Review
59 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2018, worth a combined $24.3M — down 5.8% from $25.8M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ZYNE and 18 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, adding an estimated $1.24M. The largest seller was BlackRock, cutting an estimated $4.89M.
- 59 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2018, down from 61 in Q1 2018.
- Funds reported $24.3M of Zynerba Pharmaceuticals, Inc stock for Q2 2018, down 5.8% quarter-over-quarter.
- 18 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2018 and 20 closed out, a net change of -2 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2018 was Millennium Management, an estimated $1.24M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q2 2018 was BlackRock, an estimated $4.89M sold.
Based on aggregated 13F filings for Q2 2018.